Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design
Titel:
Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design
Auteur:
Walsh, Liron Reilly, John F. Cornwall, Caitlin Gaich, Gregory A. Gipson, Debbie S. Heerspink, Hiddo J.L. Johnson, Leslie Trachtman, Howard Tuttle, Katherine R. Farag, Youssef M.K. Padmanabhan, Krishna Pan-Zhou, Xin-Ru Woodworth, James R. Czerwiec, Frank S.